Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H43N3O4 |
| Molecular Weight | 437.6159 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@@H](\C=C(/C)C(O)=O)N(C)C(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C(C)(C)C
InChI
InChIKey=FWYMMXUDTATKLG-PGLMLKKXSA-N
InChI=1S/C24H43N3O4/c1-15(2)19(14-17(5)23(30)31)26(9)22(29)20(24(6,7)8)25-21(28)18-12-10-11-13-27(18)16(3)4/h14-16,18-20H,10-13H2,1-9H3,(H,25,28)(H,30,31)/b17-14+/t18-,19-,20-/m1/s1
| Molecular Formula | C24H43N3O4 |
| Molecular Weight | 437.6159 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:47:46 GMT 2023
by
admin
on
Fri Dec 15 15:47:46 GMT 2023
|
| Record UNII |
1BO0C11BSH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10127315
Created by
admin on Fri Dec 15 15:47:46 GMT 2023 , Edited by admin on Fri Dec 15 15:47:46 GMT 2023
|
PRIMARY | |||
|
610787-07-0
Created by
admin on Fri Dec 15 15:47:46 GMT 2023 , Edited by admin on Fri Dec 15 15:47:46 GMT 2023
|
PRIMARY | |||
|
DTXSID101026331
Created by
admin on Fri Dec 15 15:47:46 GMT 2023 , Edited by admin on Fri Dec 15 15:47:46 GMT 2023
|
PRIMARY | |||
|
C49083
Created by
admin on Fri Dec 15 15:47:46 GMT 2023 , Edited by admin on Fri Dec 15 15:47:46 GMT 2023
|
PRIMARY | |||
|
1BO0C11BSH
Created by
admin on Fri Dec 15 15:47:46 GMT 2023 , Edited by admin on Fri Dec 15 15:47:46 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The invention relates to unsolvated and host-guest solvated crystalline forms of (2E,4S)-4-((N-(((2R)-l-isopropylpiperidin-2-yl)- carbonyl)-3-methyl -L-valyl) (methyl)amino)-2,5-dimethylhex-2-enoic acid, E7974, and their therapeutic uses. Pharmaceutical compositions containing crystalline forms of E7974 and a pharmaceuticall acceptable carrier represent one embodiment of the invention. The invention also relates t methods for treating cancer, an inflammatory disorder, an autoimmune disorder, or a proliferative disorder as well as restenosis of blood vessels comprising the step of administering to a patient in need thereof a therapeutically effective amount of crystalline E7974.
|
||
|
ACTIVE MOIETY |
Hemiasterlin analogue E7974: An analogue of the sponge-derived anti-microtubule tripeptide hemiasterlin with antimitotic and potential antineoplastic activities. Hemiasterlin analogue E7974 binds to the Vinca domain on tubulin, resulting in inhibition of tubulin polymerization and microtubule assembly; depolymerization of exsiting microtubules; inhibition of mitosis; and inhibition of cellular proliferation. This agent may have more affinity for the beta-3 tubulin isotype. Check for active clinical trials using this agent. (NCI Thesaurus)
|
